|
Prana Biotechnology Limited (ADR) (PRAN) news: Bipolar Prana: PBT2 For …
Seeking Alpha The REACH2HD results were encouraging as the hurdles for PBT2's use in Huntington's disease will be much lower, but it is the Alzheimer's dementia indication where the big money lies. At a market capitalisation approaching $500m, PRAN no longer has … |
